Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HitGen Subsidiary Forms Partnership to Develop Novel Cancer Drug

publication date: Nov 1, 2021

A HitGen subsidiary has formed a new company to discover small molecule inhibitors for undisclosed oncology targets. The HitGen subsidiary, Vernalis Research of Cambridge UK, joined with Copenhagen's Hannibal Innovation to create Dania Therapeutics. Dania will develop novel drug candidates based on innovative science from the labs of Professor Kristian Helin at the University of Copenhagen and Dr. Karl Agger. Dr Helin's research has centered on cell cycle control, epigenetics and cancer. Vernalis will earn equity in Dania in return for its services. HitCen is based in Chengdu. More details....

Stock Symbol: (SHA: 688222)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.